[144] Ionis Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Ionis Pharmaceuticals, Inc. notified the market of a proposed sale of 13,050 shares of its common stock through Stifel Nicolaus & Company Inc., with an approximate aggregate market value of $711,418.00. The filing states the shares represent part of outstanding common stock of 159,391,229 shares and lists an approximate sale date of 09/02/2025 on Nasdaq. The filer acquired these shares on 01/04/2021 by exercising options from the issuer and plans to receive cash as payment. The notice reports no securities sold in the past three months for the account and includes the required representation that the seller is not aware of any undisclosed material adverse information.

Positive

• Full disclosure of transaction details including broker, share count, aggregate value, exchange, and planned sale date
• Acquisition method specified (option exercise on 01/04/2021), clarifying provenance of the shares
• No sales in the prior three months reported for the account

Negative

• Insider proposes to sell 13,050 shares, which may be interpreted by some investors as insider liquidity
• Aggregate market value is $711,418, a nontrivial amount though materiality to the company is not specified in the filing

Insights

Securities/Equity Analyst

TL;DR: Routine insider sale notice of 13,050 shares valued at $711k; transaction stems from a prior option exercise.

The Form 144 documents a planned sale through a broker with explicit trade details: share count, aggregate value, exchange, and acquisition method (option exercise on 01/04/2021). This is a compliance-driven disclosure required for certain insider sales, not an earnings or corporate-operational update. The absence of any reported sales in the prior three months is notable as it suggests this is a discrete transaction rather than part of an active selling pattern based on the filing alone.

Corporate Governance / Compliance Analyst

TL;DR: Filing meets Rule 144 disclosure requirements; includes broker, acquisition detail, and seller representation.

The document provides the elements regulators and market participants expect for a Rule 144 notice: broker identity (Stifel Nicolaus), acquisition method (option exercise), planned sale date, and the seller's attestation regarding material nonpublic information. The filing also explicitly states there were no securities sold in the prior three months for the account, which is relevant to aggregation rules under Rule 144. From a compliance perspective, the notice appears complete for its purpose.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	13050	711418.00	159391229	09/02/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/04/2021	Option Exercise	Issuer			13050	09/02/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is Ionis Pharmaceuticals (IONS) proposing to sell according to this Form 144?

The filing proposes the sale of 13,050 shares of Ionis common stock through Stifel Nicolaus, with an aggregate market value of $711,418.00.

When is the proposed sale date listed in the Form 144 for IONS?

The approximate date of sale is listed as 09/02/2025.

How were the shares being sold acquired, per the filing?

The shares were acquired by option exercise on 01/04/2021, with payment to be in cash.

Did the filer report any securities sold in the past three months?

The filing states Nothing to Report for securities sold during the past three months for the account.

Which broker is handling the proposed sale of Ionis shares?

The broker named in the filing is Stifel Nicolaus & Company Inc.